Pharmacology: DDB was shown to protect against hepatic injury induced by chemical toxins eg, prednisolone, carbon tetrachloride, thioacetamide and D-galactosamine in mice and rabbits. DDB inhibits carbon tetrachloride-induced lipid peroxidation of liver microsomes and the covalent binding of carbon tetrachloride to microsomal lipids. In addition, DDB significantly increased the liver detoxicating ability and antagonized the mutagenicity of chemical carcinogens eg, aflatoxin B and benz(a)pyrene.
Toxicology: The toxicity of DDB is very low.
Carcinogenicity & Mutagenicity: No teratogenic or mutagenic effect was detected.
Clinical Effects: Rapid drop in SGPT. The elevated SGPT levels of 80-85% of the patients returned to normal after treatment.
Restoring normal ratio of serum albumin and globulin (A/G), and improving thymol fluctuation test (TFT).
Decreasing the elevated serum α-fetal protein (α-FP) and bilirubin at an effective rate of 80%.
Relieving symptoms eg, hepatic pain, fatigue, abdominal tension and anorexia.
Ameliorating liver pathological changes. Such improvements can be examined through the liver biopsies performed before and after treatment.
The SGPT-lowering effect of DDB in the patients was found to be much better than that of silymarin (Legalon) and glycyrrhizin (Stronger Neo Minophagen C).
No side effects of DDB have been observed.